Key result
Sarafotoxins 6a and 6c induce pulmonary vasoconstriction independent of cyclooxygenase or thromboxane A2 pathways.
Why the study?
Pulmonary vascular responses to sarafotoxins 6a and 6c in the intact-chest cat under constant flow conditions were not fully characterized.
Should not guide human pulmonary hypertension therapy; leaves open sarafotoxin–endothelin parallels for mechanistic study.
Pulmonary vascular responses to sarafotoxins 6a and 6c (S6a and S6c) were investigated in the intact-chest cat under constant flow conditions. Injections of S6a and S6c into the perfused lobar artery caused dose-related increases in lobar arterial pressure, increased left atrial pressure, and produced biphasic changes in systemic arterial (aortic) pressure. When left atrial pressure was maintained constant, injections of S6a, S6c, and endothelin 1 (ET-1) caused dose-related increases in lobar arterial pressure. The increases in lobar arterial pressure in response to S6a and S6c were not altered by treatment with a cyclooxygenase inhibitor or a thromboxane receptor blocking agent. Increases in lobar arterial pressure in response to S6a and S6c were not altered when airflow to the left lower lung lobe was interrupted by bronchial occlusion, and pressor responses were not diminished when the left lower lobe was perfused with low-molecular-weight dextran. Under conditions of controlled blood flow and constant left atrial pressure, S6a, S6b, S6c, and ET-1 had similar pressor activity, whereas the thromboxane A2 mimic, U-46619, had far greater activity when compared on a nanomolar basis. The present studies demonstrate that S6a and S6c have significant vasoconstrictor activity in the feline pulmonary vascular bed. These data suggest that pulmonary vasoconstrictor responses to the endothelin peptides are not dependent on release of cyclooxygenase products and the activation of thromboxane A2 receptors, alterations in bronchomotor tone, or interaction with formed elements in blood.
No takes yet. Share an insight, caveat, or question.
McMahon et al. (1991) studied this question. Sarafotoxins 6a and 6c vs. Endothelin 1 (ET-1) and U-46619 was evaluated on Pulmonary vascular responses (lobar arterial pressure). Sarafotoxins 6a and 6c demonstrated significant vasoconstrictor activity in the feline pulmonary vascular bed, independent of cyclooxygenase products or thromboxane A2 receptors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: